Neovacs S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was EUR 0.538289 million compared to EUR 0.012555 million a year ago. Net loss was EUR 8.74 million compared to EUR 3.55 million a year ago.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0177 EUR | -2.75% | -40.00% | -99.12% |
Jun. 17 | Neovacs: collaboration agreement with CNRS | CF |
Jun. 10 | Neovacs: presents results from vaccine candidates | CF |
1st Jan change | Capi. | |
---|---|---|
-99.12% | 77.24K | |
+38.87% | 39.1B | |
-7.84% | 38.76B | |
+27.16% | 31.24B | |
+11.86% | 25.9B | |
-13.75% | 25.8B | |
+45.28% | 14.06B | |
+39.56% | 13.12B | |
-6.67% | 11.32B | |
-11.78% | 10.68B |
- Stock Market
- Equities
- ALNEV Stock
- News NEOVACS
- Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2023